Atlas Trials

Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

Clinical trial NCT05937906 · RECRUITING

Trial details

NCT number
NCT05937906
Sponsor
Centre Georges Francois Leclerc
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2026-07-07
Primary completion
2028-07-25
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.